Market Research Logo

Multiple Sclerosis - Pipeline Review, H1 2015

Multiple Sclerosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H1 2015’, provides an overview of the Multiple Sclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Multiple Sclerosis Overview
Therapeutics Development
Multiple Sclerosis - Therapeutics under Development by Companies
Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes
Multiple Sclerosis - Pipeline Products Glance
Multiple Sclerosis - Products under Development by Companies
Multiple Sclerosis - Products under Investigation by Universities/Institutes
Multiple Sclerosis - Companies Involved in Therapeutics Development
Multiple Sclerosis - Therapeutics Assessment
Drug Profiles
Multiple Sclerosis - Recent Pipeline Updates
Multiple Sclerosis - Dormant Projects
Multiple Sclerosis - Discontinued Products
Multiple Sclerosis - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2015
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Development by Companies, H1 2015 (Contd..12)
Number of Products under Development by Companies, H1 2015 (Contd..13)
Number of Products under Development by Companies, H1 2015 (Contd..14)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3)
Multiple Sclerosis - Pipeline by 4SC AG, H1 2015
Multiple Sclerosis - Pipeline by AB Science, H1 2015
Multiple Sclerosis - Pipeline by AbbVie Inc., H1 2015
Multiple Sclerosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2015
Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Actelion Ltd, H1 2015
Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2015
Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H1 2015
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2015
Multiple Sclerosis - Pipeline by AiCuris GmbH & Co. KG, H1 2015
Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2015
Multiple Sclerosis - Pipeline by Allozyne, Inc., H1 2015
Multiple Sclerosis - Pipeline by Amarna Therapeutics B.V., H1 2015
Multiple Sclerosis - Pipeline by Antipodean Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by Antisense Therapeutics Limited, H1 2015
Multiple Sclerosis - Pipeline by Antitope Limited, H1 2015
Multiple Sclerosis - Pipeline by Aphios Corporation, H1 2015
Multiple Sclerosis - Pipeline by Apitope International NV, H1 2015
Multiple Sclerosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Array BioPharma Inc., H1 2015
Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015
Multiple Sclerosis - Pipeline by Athersys, Inc., H1 2015
Multiple Sclerosis - Pipeline by Axxam SpA, H1 2015
Multiple Sclerosis - Pipeline by Baliopharm AG, H1 2015
Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Limited, H1 2015
Multiple Sclerosis - Pipeline by BIOCAD, H1 2015
Multiple Sclerosis - Pipeline by Biocon Limited, H1 2015
Multiple Sclerosis - Pipeline by Biogen, Inc., H1 2015
Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H1 2015
Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2015
Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H1 2015
Multiple Sclerosis - Pipeline by Bioncotech Therapeutics S.L., H1 2015
Multiple Sclerosis - Pipeline by Bionomics Limited, H1 2015
Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H1 2015
Multiple Sclerosis - Pipeline by Biovista Inc., H1 2015
Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H1 2015
Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2015
Multiple Sclerosis - Pipeline by Caladrius Biosciences, Inc. , H1 2015
Multiple Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc., H1 2015
Multiple Sclerosis - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015
Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H1 2015
Multiple Sclerosis - Pipeline by Cellceutix Corporation, H1 2015
Multiple Sclerosis - Pipeline by Cognosci, Inc., H1 2015
Multiple Sclerosis - Pipeline by Compugen Ltd., H1 2015
Multiple Sclerosis - Pipeline by Creabilis SA, H1 2015
Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H1 2015
Multiple Sclerosis - Pipeline by Daval International Limited, H1 2015
Multiple Sclerosis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015
Multiple Sclerosis - Pipeline by Digna Biotech, S.L., H1 2015
Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015
Multiple Sclerosis - Pipeline by Dong-A Socio Group, H1 2015
Multiple Sclerosis - Pipeline by Effimune SAS, H1 2015
Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H1 2015
Multiple Sclerosis - Pipeline by Endece, LLC, H1 2015
Multiple Sclerosis - Pipeline by Evgen Limited, H1 2015
Multiple Sclerosis - Pipeline by Evotec AG, H1 2015
Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2015
Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015
Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2015
Multiple Sclerosis - Pipeline by Genmab A/S, H1 2015
Multiple Sclerosis - Pipeline by Genzyme Corporation, H1 2015
Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2015
Multiple Sclerosis - Pipeline by GliaCure Inc., H1 2015
Multiple Sclerosis - Pipeline by Glialogix, Inc., H1 2015
Multiple Sclerosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Multiple Sclerosis - Pipeline by Hanwha Chemical Corporation, H1 2015
Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H1 2015
Multiple Sclerosis - Pipeline by Idera Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by Iltoo Pharma, H1 2015
Multiple Sclerosis - Pipeline by Immunaffect B.V., H1 2015
Multiple Sclerosis - Pipeline by Immune Response BioPharma, Inc., H1 2015
Multiple Sclerosis - Pipeline by ImmuNext, Inc., H1 2015
Multiple Sclerosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Multiple Sclerosis - Pipeline by InDex Pharmaceuticals AB, H1 2015
Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Limited, H1 2015
Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by InteKrin Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Invion Limited, H1 2015
Multiple Sclerosis - Pipeline by Io Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Kadimastem Ltd., H1 2015
Multiple Sclerosis - Pipeline by Kadmon Corporation, LLC, H1 2015
Multiple Sclerosis - Pipeline by KAHR medical Ltd., H1 2015
Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by Kareus Therapeutics, SA, H1 2015
Multiple Sclerosis - Pipeline by Karo Bio AB, H1 2015
Multiple Sclerosis - Pipeline by Kineta, Inc., H1 2015
Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015
Multiple Sclerosis - Pipeline by Lanthio Pharma B.V., H1 2015
Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2015
Multiple Sclerosis - Pipeline by Longevity Biotech, Inc, H1 2015
Multiple Sclerosis - Pipeline by MacroGenics, Inc., H1 2015
Multiple Sclerosis - Pipeline by MAKScientific, LLC, H1 2015
Multiple Sclerosis - Pipeline by Mapi Pharma Ltd., H1 2015
Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2015
Multiple Sclerosis - Pipeline by MedDay, H1 2015
Multiple Sclerosis - Pipeline by MedImmune, LLC, H1 2015
Multiple Sclerosis - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015
Multiple Sclerosis - Pipeline by Merck KGaA, H1 2015
Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2015
Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Multiple Sclerosis - Pipeline by MSM Protein Technologies, Inc., H1 2015
Multiple Sclerosis - Pipeline by Neuralstem, Inc., H1 2015
Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Limited, H1 2015
Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H1 2015
Multiple Sclerosis - Pipeline by Nordic Life Science Pipeline Inc., H1 2015
Multiple Sclerosis - Pipeline by Novartis AG, H1 2015
Multiple Sclerosis - Pipeline by Nuron Biotech, Inc., H1 2015
Multiple Sclerosis - Pipeline by Ocata Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Octapharma AG, H1 2015
Multiple Sclerosis - Pipeline by Omeros Corporation, H1 2015
Multiple Sclerosis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Multiple Sclerosis - Pipeline by Opexa Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by OPKO Health, Inc., H1 2015
Multiple Sclerosis - Pipeline by Padlock Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Peptinov SAS, H1 2015
Multiple Sclerosis - Pipeline by Pfenex Inc., H1 2015
Multiple Sclerosis - Pipeline by Pfizer Inc., H1 2015
Multiple Sclerosis - Pipeline by PharmatrophiX, Inc., H1 2015
Multiple Sclerosis - Pipeline by Pieris AG, H1 2015
Multiple Sclerosis - Pipeline by Plexxikon Inc., H1 2015
Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2015
Multiple Sclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by RAPID Pharmaceuticals AG, H1 2015
Multiple Sclerosis - Pipeline by Receptos, Inc., H1 2015
Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd., H1 2015
Multiple Sclerosis - Pipeline by Regenesance BV, H1 2015
Multiple Sclerosis - Pipeline by Resverlogix Corp., H1 2015
Multiple Sclerosis - Pipeline by ReveraGen BioPharma, Inc., H1 2015
Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by SanBio, Inc., H1 2015
Multiple Sclerosis - Pipeline by Sanofi, H1 2015
Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015
Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2015
Multiple Sclerosis - Pipeline by Siena Biotech S.p.A., H1 2015
Multiple Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Multiple Sclerosis - Pipeline by SOM Innovation Biotech SL, H1 2015
Multiple Sclerosis - Pipeline by Sorrento Therapeutics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Synthetic Biologics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2015
Multiple Sclerosis - Pipeline by Targazyme, Inc., H1 2015
Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H1 2015
Multiple Sclerosis - Pipeline by TikoMed AB, H1 2015
Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2015
Multiple Sclerosis - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015
Multiple Sclerosis - Pipeline by Vaccinex, Inc., H1 2015
Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2015
Multiple Sclerosis - Pipeline by Varinel, Inc., H1 2015
Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015
Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2015
Multiple Sclerosis - Pipeline by Virogenomics, Inc., H1 2015
Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2015
Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2015
Multiple Sclerosis - Pipeline by Xenetic Biosciences plc, H1 2015
Multiple Sclerosis - Pipeline by XenoPort, Inc., H1 2015
Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2015
Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Multiple Sclerosis Therapeutics - Recent Pipeline Updates, H1 2015
Multiple Sclerosis - Dormant Projects, H1 2015
Multiple Sclerosis - Dormant Projects (Contd..1), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..2), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..3), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..4), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..5), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..6), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..7), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..8), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..9), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..10), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..11), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..12), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..13), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..14), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..15), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..16), H1 2015
Multiple Sclerosis - Dormant Projects (Contd..17), H1 2015
Multiple Sclerosis - Discontinued Products, H1 2015
Multiple Sclerosis - Discontinued Products (Contd..1), H1 2015
Multiple Sclerosis - Discontinued Products (Contd..2), H1 2015
Multiple Sclerosis - Discontinued Products (Contd..3), H1 2015
Multiple Sclerosis - Discontinued Products (Contd..4), H1 2015
List of Figures
Number of Products under Development for Multiple Sclerosis, H1 2015
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report